What we do Concord Biotech Limited is an India-based biopharma company specializing in fermentation-based Active Pharmaceutical Ingredients and formulations, serving over 70 countries including the US, Europe, and Japan. |
Founded in 1,984 |
Market share A leading global developer and manufacturer of select fermentation-based APIs with significant market share in immunosuppressants and oncology. |
Problem solved Provides high-quality fermentation-based APIs and formulations addressing critical needs in immunosuppressant and oncology therapy worldwide. |
Top clients or who we serve Serves global pharmaceutical companies across regulated and emerging markets through B2B and B2C channels, with 250+ customers in 70+ countries. |
Key management - |
Our journey and innovations Established in 1984, expanded with acquisitions and new formulations since 2016, launched injectable facility in 2025, and expanded global footprint including strategic JV in Japan. |
Where we operate Operations in India with exports to over 70 countries including the US, Europe, Japan, Middle East, and emerging markets. |
Top products or what we offer Manufactures over 30 fermentation-based APIs across immunosuppressants, oncology, anti-infectives along with 100+ formulation products including injectables and oral dosages. |
Top brands Key API brands include Tacrolimus, Mycophenolate Mofetil, Cyclosporine; formulation brands include Tacrocord, Mepecon, Dapute; gaining approvals in US, EU, South Korea, Russia. |
Raw materials needed Key starting materials for fermentation-based API manufacturing including microbial strains and chemical precursors for semi-synthesis. |
Raw materials supplier Suppliers include specialized chemical providers and microbial strain developers; precise supplier names are confidential. |
Recurring vs cyclical contribution Majority revenue is recurring from long-term supply contracts of APIs and formulations with stable demand in chronic therapies. |
Our industry position Among top global players in fermentation-based APIs with strong regulatory compliance and expanding formulation business. |
Financial highlights FY25 revenue of Rs 1200 Crores with Rs 371 Crores net profit, showing 18% YoY revenue growth and healthy EBITDA margins around 40%. |
Geographical revenue split 55% revenue from India, 45% from exports including America and other global markets. |
Order book - |
Whats driving growth Growth driven by expansion in injectable formulations, new product launches, regulatory approvals, and strategic investments in biotech and renewable energy. |
Our future plans Focus on scaling injectable facility, launching pipeline products, expanding US and emerging markets, and investing in sustainable manufacturing. |
Our green promise Committed to sustainability with investments in renewable energy, ISO certifications, and awarded for sustainability reporting excellence. |
Our people and values Strong R&D team of 180+, fostering innovation, ethical governance, diversity and inclusion in corporate culture. |
Key challenges ahead Regulatory delays, geopolitical tensions impacting tenders, and global trade uncertainties pose ongoing risks. |
Interesting facts Holds one of the world's largest fermentation capacities with 1,250 m3, recognized with prestigious manufacturing and sustainability awards. |
Risks and strategy Mitigates risks through regulatory compliance, diversification across markets and products, and continuous innovation and strategic partnerships. |
